GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Shiller PE Ratio

Seagen (Seagen) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Seagen Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Seagen Shiller PE Ratio Historical Data

The historical data trend for Seagen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Shiller PE Ratio Chart

Seagen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Seagen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Seagen's Shiller PE Ratio

For the Biotechnology subindustry, Seagen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seagen's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seagen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Seagen's Shiller PE Ratio falls into.



Seagen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Seagen's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Seagen's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-1.15/129.8595*129.8595
=-1.150

Current CPI (Sep. 2023) = 129.8595.

Seagen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.130 98.326 -0.172
201403 -0.130 99.695 -0.169
201406 -0.140 100.560 -0.181
201409 -0.130 100.428 -0.168
201412 -0.220 99.070 -0.288
201503 -0.170 99.621 -0.222
201506 -0.380 100.684 -0.490
201509 -0.210 100.392 -0.272
201512 -0.180 99.792 -0.234
201603 -0.150 100.470 -0.194
201606 -0.230 101.688 -0.294
201609 -0.230 101.861 -0.293
201612 -0.390 101.863 -0.497
201703 -0.420 102.862 -0.530
201706 -0.390 103.349 -0.490
201709 0.340 104.136 0.424
201712 -0.410 104.011 -0.512
201803 -0.730 105.290 -0.900
201806 0.470 106.317 0.574
201809 -0.420 106.507 -0.512
201812 -0.750 105.998 -0.919
201903 -0.080 107.251 -0.097
201906 -0.490 108.070 -0.589
201909 -0.550 108.329 -0.659
201912 0.140 108.420 0.168
202003 -0.980 108.902 -1.169
202006 -0.120 108.767 -0.143
202009 3.500 109.815 4.139
202012 0.900 109.897 1.063
202103 -0.670 111.754 -0.779
202106 -0.470 114.631 -0.532
202109 -1.610 115.734 -1.806
202112 -0.950 117.630 -1.049
202203 -0.740 121.301 -0.792
202206 -0.730 125.017 -0.758
202209 -1.030 125.227 -1.068
202212 -0.800 125.222 -0.830
202303 -0.930 127.348 -0.948
202306 -1.130 128.729 -1.140
202309 -1.150 129.860 -1.150

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Seagen  (NAS:SGEN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Seagen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Seagen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Seagen (Seagen) Business Description

Traded in Other Exchanges
N/A
Address
21823 - 30th Drive South East, Bothell, WA, USA, 98021
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Executives
David R Epstein director, officer: Chief Executive Officer INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes officer: See Remarks C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp officer: EVP, Commercial 21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu officer: GC & EVP, Legal Affairs 21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson officer: Chief Financial Officer
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain director 21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Seagen (Seagen) Headlines

From GuruFocus

This Insider Just Sold Shares of Seagen Inc

By GuruFocus Research GuruFocus Editor 05-19-2023

Should Investors Worry About Seagen Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-20-2023